Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy.
作者信息
Cheung Chee Kay, Barratt Jonathan
机构信息
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom.
出版信息
J Am Soc Nephrol. 2022 May;33(5):873-875. doi: 10.1681/ASN.2022020201. Epub 2022 Apr 7.
Abstract
摘要
相似文献
1
Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy.
J Am Soc Nephrol. 2022 May;33(5):873-875. doi: 10.1681/ASN.2022020201. Epub 2022 Apr 7.
2
Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
J Am Soc Nephrol. 2022 May;33(5):908-917. doi: 10.1681/ASN.2021081086. Epub 2022 Feb 3.
3
Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1.
Nephrol Dial Transplant. 2010 May;25(5):1708-13. doi: 10.1093/ndt/gfp693. Epub 2010 Jan 12.
4
[IgA1 aberrant glycosylation in the pathogenesis of IgA nephropathy: an overivew].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Feb;27(1):227-30.
5
Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
Clin Immunol. 2020 Aug;217:108483. doi: 10.1016/j.clim.2020.108483. Epub 2020 May 30.
6
Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.
J Am Soc Nephrol. 2016 Nov;27(11):3278-3284. doi: 10.1681/ASN.2014101044. Epub 2016 Mar 10.
7
Interaction between and Associates with Galactose-Deficient IgA1 and IgA Nephropathy.
J Am Soc Nephrol. 2021 Mar;32(3):545-552. doi: 10.1681/ASN.2020060823. Epub 2021 Feb 16.
8
Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.
Sci Rep. 2020 Aug 20;10(1):14026. doi: 10.1038/s41598-020-71101-y.
9
Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura.
Pediatr Nephrol. 2007 Dec;22(12):2067-72. doi: 10.1007/s00467-007-0623-y. Epub 2007 Oct 18.
10
Glycosylation of IgA1 and pathogenesis of IgA nephropathy.
Semin Immunopathol. 2012 May;34(3):365-82. doi: 10.1007/s00281-012-0306-z. Epub 2012 Mar 21.
引用本文的文献
1
Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy.
MedComm (2020). 2025 Sep 8;6(9):e70382. doi: 10.1002/mco2.70382. eCollection 2025 Sep.
2
What's new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney.
J Pathol Transl Med. 2025 Jul;59(4):269-272. doi: 10.4132/jptm.2025.06.19. Epub 2025 Jul 10.
3
APRIL: spring forward also for IgA vasculitis nephritis in children.
Pediatr Nephrol. 2025 Jun 11. doi: 10.1007/s00467-025-06839-6.
4
IgA nephropathy and IgA vasculitis in a pediatric Crohn's disease patient with early IgA deposition in vascular walls of intestines.
CEN Case Rep. 2025 Feb 26. doi: 10.1007/s13730-025-00970-x.
5
New Insights and Future Perspectives of APRIL in IgA Nephropathy.
Int J Mol Sci. 2024 Sep 26;25(19):10340. doi: 10.3390/ijms251910340.
6
Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.
Front Med. 2024 Oct;18(5):862-877. doi: 10.1007/s11684-024-1086-2. Epub 2024 Sep 30.
7
The pathogenesis of IgA nephropathy and implications for treatment.
Nat Rev Nephrol. 2025 Jan;21(1):9-23. doi: 10.1038/s41581-024-00885-3. Epub 2024 Sep 4.
8
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.
Front Nephrol. 2024 Feb 1;3:1346769. doi: 10.3389/fneph.2023.1346769. eCollection 2023.
9
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29.
10
The pathological and outcome characteristics of renal lesions in Crohn's disease.
BMC Nephrol. 2022 Jul 18;23(1):256. doi: 10.1186/s12882-022-02883-8.
本文引用的文献
1
Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
J Am Soc Nephrol. 2022 May;33(5):908-917. doi: 10.1681/ASN.2021081086. Epub 2022 Feb 3.
2
Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link.
Int J Immunogenet. 2022 Feb;49(1):8-21. doi: 10.1111/iji.12561. Epub 2021 Nov 24.
3
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients.
Nephrol Dial Transplant. 2021 Aug 27;36(9):1765. doi: 10.1093/ndt/gfaa344.
4
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.
5
Lambda light chain revision in the human intestinal IgA response.
J Immunol. 2008 Jul 15;181(2):1264-71. doi: 10.4049/jimmunol.181.2.1264.
6
Human autoantibody silencing by immunoglobulin light chains.
J Exp Med. 2004 Jul 19;200(2):191-9. doi: 10.1084/jem.20040818.
7
Predominant synthesis of IgA with lambda light chain in IgA nephropathy.
Kidney Int. 1988 Feb;33(2):584-9. doi: 10.1038/ki.1988.37.
Zotero 插件